Kornimate/medical-research-clean huggingface dataset:
internet-based cognitive behavioural therapy for cardiac patients

Conditions: Depression; Cardiovascular Diseases

Summary: our overall objective is to evaluate the efficacy of therapist-assisted, internet-based cognitive-behavioural therapy (icbt) for depressed cardiac patients with respect to clinical outcomes, and the feasibility of the program. our primary outcome will be depression severity; secondary outcomes will be hospitalization for a cardiac cause, recurrent myocardial infarction or revascularization. the study will inform a proposal to incorporate icbt into the resources routinely available to cardiac patients following hospitalization for a cardiac event.

we are planning we are planning a single-arm, open label trial to evaluate the feasibility, acceptability and efficacy of icbt among persistently depressed cardiac patients. cardiac patients will be recruited from inpatient units in a university-affiliated hospital and screened for depression at 4 and possibly 8 or 12 weeks following discharge. eligible patients will be enrolled in the icbt program.data regarding the primary outcome, improvement in depression severity, will be collected at completion of the intervention and at 8 weeks after completion. in addition to depression severity data, we will also obtain other data related to clinical feasibility, such as treatment adherence and the acceptability of the intervention to patients. self-reported rates of hospital readmission or emergency visits for a cardiac cause will also be tracked.

Eligibility criteria:
inclusion criteria: * admitted to one of study units with any cardiac diagnosis or cardiac procedure on this admission * able to speak and read english * able to provide informed consent and participate in therapy * access to and ability to use a computer with internet access. between 4 and 12 weeks after discharge, consenting participants will be required to meet a further inclusion criterion of: • current depressive symptoms of at least mild severity on 2 successive assessments, 4 weeks apart or a single assessment of mild symptoms at 12 weeks post-discharge. exclusion criteria: applied at screening (and criteria 1 and 2 reapplied before enrolment): 1. active suicidal ideation (since this requires immediate referral for intense psychiatric care) 2. previous suicide attempt 3. currently undergoing psychotherapy for depression 4. receiving antidepressant medication that has been initiated or adjusted within previous 3 months 5. concurrent psychiatric disorder, other than anxiety; 6. self-reported substance misuse within past 6 months 7. concurrent terminal illness 8. clinical status interfering with ability to independently engage in icbt.

Keywords: icbt cardiac event cognitive behavioural therapy depression
pre-biopsy with dynamic acquisitions

Conditions: Breast Cancer

Summary: this study is being done to test the ability of an investigational mammography camera to find small tumors in patients' breasts.

if you agree to take part in this study, you will be asked to remove your clothes from the waist up and put on a gown. a female technologist will give you an injection of tc-99m sestamibi in a vein in your arm. this is a drug routinely used for breast imaging. about 10 minutes after your injection, you will be asked to sit in a chair for about 40 minutes. the technologist will position your breast between two small cameras. the cameras will apply a very light compression to your breast to make sure there is no movement during the picture. we will take two pictures of each breast. each picture takes 10 minutes. you will also be asked to fill out a short questionnaire. if you are found to have additional breast lesions, your doctor and radiologist will be notified so that additional imaging or biopsies can be performed.

Eligibility criteria:
inclusion criteria: * have a lesion on mammogram, ultrasound or mri that measured \< 2 cm and considered suspicious or suggestive of malignancy * scheduled for biopsy of lesion * \> 18 years of age * negative pregnancy test, postmenopausal, or surgically sterilized exclusion criteria: * prior needle biopsy

Keywords: mbi breast breast cancer
quality of life and visual acuity of visglyc eye drops on dry eye patients

Conditions: Dry Eye Syndromes; Cataract

Summary: clinical trial with medical devices, post-authorization, parallel, single-blind, randomized, comparative, prospective to study how afects the quality of life the use of ocular eye drops on patients with dry eye symptomatology and age-related loss of visual acuity. secondary purposes: efects on the dry eye symptomatology, efect on visual acuity and treatment adherence.


Eligibility criteria:
inclusion criteria: * subjects between the ages of 50 and 70. * subjects with initial or slight changes characteristic of cataracts (grade 1-3 according to locs iii classification). * subjects with dry eye symptoms. * confirmation of senile cataract diagnosis according to medical history and clinical observations, bilateral. * visual acuity equal to or greater than (0.6) in both eyes (with the best correction). * cataracts without the need for surgical intervention in the near future (1 year) based on the visual needs of the patient and ocular symptomatology. * subjects that have not undergone cataract surgery. * cases that do not accept surgery (weak corneas, high degree of myopia, sensitivity to light, severe dryness of the eyes or by their own decision). * subjects who agree to sign the ic (informed consent). exclusion criteria: * subjects with eye diseases such as glaucoma or diabetic retinopathy. * previous laser photocoagulation of the retina. * previous corneal or anterior segment surgery or previous corneal scars that may interfere with visualization or photographs. * presence of mature cataracts (grade 4-5/6 according to locs iii classification) in both eyes. * candidates for surgery in the following year. * subjects with monocular aphakia (absence of crystalline lens) or secondary cataracts (associated with steroid use, local or total irradiation, local inflammation or degenerative processes, ocular trauma). * subjects with known hypersensitivity to any component of ophthalmic treatment. * subjects treated with drugs that may interfere with the evolution of the disease under study. * subjects who wear contact lenses. * pregnant women. * breastfeeding women. * subjects who have participated in another clinical trial within the last 30 days. * subjects with linguistic or psychological incapacity to understand and sign the ci.

Keywords: dry eye cataract visual acuity quality of life eye drops dry eye symptomatology n-acetylcarnosine vaccinium myrtillus chondroitin sulfate chondroitin sulphate n-acetylcharnosine
early skin to skin in neonatal reanimation

Conditions: Infant, Premature

Summary: in the reanimation neonatal department of the nice's hospital, 34% of newborns admitted have an umbilical vein catheter (ktvo). their parents are admitted 24h/24h by their side, where everything is done to set up the attachment (participation in care, skin to skin, support of breastfeeding, ...). the benefits of skin to skin described in developmental care of the newborn in the neonatal health services are well established. nevertheless, for supposed risks (infectious and displacement of the catheter), registered in the memory of the teams, this care is not currently carried out when the newborns are carrying an umbilical venous catheter. sometimes, because of the presence of an umbilical venous catheter, parents and their newborns could not enjoy this moment of well-being in the first days of life. we therefore propose a study evaluating the current risks of skin to skin with an umbilical venous catheter by reflecting on a new protocol for laying and fixing this medical device.


Eligibility criteria:
inclusion criteria: * newborn of gestational age less than 37sa * admitted in neonatal reanimation department at nice's hospital * born in the maternity ward of the nice's hospital * carriers of an umbilical venous catheter. exclusion criteria: * all newborns with medical contraindications from skin to skin: * controlled hypothermia protocol * newborn under hfo (high frequency oscillation) * carrying a diaphragmatic hernia * thoracic drain holder * with major pah (hypertensive pulmonary artery) * symptomatic mother of acute infectious disease * mother whose physical or psychiatric capacity is not compatible with travel to the neonatal reanimation service within 3 days of delivery. * minor mother
psa tool for prostate cancer screening discussions

Conditions: Prostate Cancer

Summary: the study team created a tool to help identify patients who may benefit from shared decision making in the primary care setting. this tool is a guide to aid in decision making for prostate cancer screening. the team proposes the topics to be discussed in the screening conversation include the risk for developing prostate cancer based upon age, race/ethnicity, family history of prostate cancer, history of previous digital rectal exam, and history of previous prostate specific antigen (psa) as well as self-reported health status and preferences for treatment. the team now proposes 1) testing this tool first for ease of use in primary care clinics 2) revising this tool based upon feedback from patients and providers, then 3) testing this tool for effectiveness in improving patient knowledge that they have an option to be screened for prostate cancer and of specific factors to be considered in the screening decision.

objectives: 1. to pilot test a decision making tool, the psa tool, for prostate cancer screening for usefulness and ease of use in primary care practices. 2. to revise the psa tool based upon provider and patient feedback. 3. to assess patient knowledge about the option to be screened for prostate cancer and factors to consider in the prostate cancer screening decision before and after use of the tool. study design: this protocol is for field testing of a brief tool to improve prostate cancer screening discussions that occur at previously scheduled primary care outpatient visits.

Eligibility criteria:
inclusion criteria: provider: * provider at selected primary care practices in the cleveland clinic health system * willing to utilize a guide to aid in decision making for prostate cancer screening patient: - patient of participating cleveland clinic primary care provider who is scheduled for a routine appointment with the provider exclusion criteria: * not a patient or provider of the cleveland clinic health system

Keywords: screening shared decision making
nasogastric/orogastric tube placement confirmation in neonates utilizing self-contained ph device, a feasibility study

Conditions: Premature Birth

Summary: this study is looking at using a self-contained ph device that will assist in confirming placement of a nasogastric or orogastric tube placed in the stomach of hospitalized infants.


Eligibility criteria:
inclusion criteria: * all patients admitted to the nicu at the university of minnesota masonic children's hospital, minneapolis, mn requiring placement of an ng/og tube are eligible to enroll. exclusion criteria: * participant deemed unsuitable for study by the treating provider. participants who are on the following medications: proton-pump inhibitor (ppi's) or h2 blockers within one week prior to the device assessment.

Keywords: prematurity nasogastric orogastric
a study of imlunestrant (ly3484356) in female participants with impaired liver function

Conditions: Hepatic Insufficiency; Healthy

Summary: the main purpose of this study is to measure how much of imlunestrant (ly3484356) gets into the bloodstream and how long it takes the body to eliminate it in female participants with impaired liver function compared to female participants with normal liver function. the side effects and tolerability of imlunestrant will also be evaluated. the study may last up to 46 days for each participant.


Eligibility criteria:
inclusion criteria: all participants: * women not of childbearing potential may participate and include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, bilateral salpingectomy or tubal ligation), congenital anomaly such as mullerian agenesis; or postmenopausal * are between the body mass index (bmi) of 18.0 and 42.0 kilograms per meter squared (kg/m²), inclusive, at screening healthy participants: - healthy females as determined by medical history, physical examination, and other screening procedures, with normal liver function participants with impaired liver function: * females with chronic mild, moderate and severe liver impairment, assessed by child-pugh scoring * have diagnosis of chronic hepatic impairment (\>6 months), with no clinically significant changes within 90 days prior to study drug administration. exclusion criteria: * women of childbearing potential are excluded from the study. * have known allergies to imlunestrant or related compounds * have a history of alcoholism or drug/chemical abuse within 2 years prior to check-in * have received blood products within 2 months prior to check-in * have evidence of hiv infection and/or positive human hiv antibodies * have used or intend to use medications that are strong inhibiters or inducers of cytochrome p450 (cyp)3a4 * who smoke more than 10 cigarettes or use the equivalent tobacco, smoking-cessation products, nicotine-containing products, or e-cigarettes (nicotine and non-nicotine) per day. * have a history or presence of cardiovascular (eg, symptomatic bradycardia with resting heart rate of \<60 beats per minute), respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
diagnostic scoring for small bowel obstruction

Conditions: Small Bowel Obstruction

Summary: it is difficult to predict which patients with acute small bowel obstruction require operative intervention and which ones can be handled conservatively. similarly, strangulation remains difficult decision. the rationale for this observative study is to collect prospective cohort of patients with small bowel obstruction to create scoring system to predict early 1) small bowel obstruction resistant to conservative therapy, 2) strangulation.


Eligibility criteria:
inclusion criteria: * computed tomography verified acute small bowel obstruction exclusion criteria: * \< 18 years old * pregnant * abdominal surgery within 30 days prior recruitment * inflammatory bowel disease * small bowel tumor causing obstruction * peritoneal carcinosis * intraluminal obstruction (bile stone, bezoar, etc.) * large bowel obstruction * small bowel obstruction caused by abdominal wall hernia
iugr; cause and relationship

Conditions: Intrauterine Growth Restriction

Summary: intrauterine growth restriction (iugr) is a pregnancy complication in about 3-5% of all pregnancies in sweden. iugr fetuses are at high risk of morbidity and death. the method used in sweden to detect iugr is repeated measurements of pregnant women's symphysis-fundus measure (sf measure). weight estimation with ultrasound is performed only on indication; stagnant or deplaning sf dimensions or in the event of complications. only high-risk pregnancies have repeated growth checks during pregnancy from the beginning. there are potential benefits to detecting iugr fetuses during pregnancy. still, the effect is questioned. a meta-analysis of randomized studies could not benefit from a routine ultrasound in the third trimester. the scientific purpose of this work is to evaluate the benefits of early detection and care of sga (small for gestational age)/iugr (growth-inhibited) fetuses and, if possible, to increase knowledge about this patient group. the hope is that this will lead to a better opportunity to personalize both preventive care and treatment of these women and children.

design: register-based cohort study. population: all pregnancies in stockholm from 2014 to 2017 a composite outcome for the study is constructed and consists of at least one of the following outcomes 1. hie (hypoxic-ischemic encephalopathy)2-3 (neonatal convulsions in the fetus after childbirth), 2. intracranial hemorrhage, 3. apgar score \< 4 at 5 minutes, 4. arterial umbilical cord ph (potential of hydrogen) \< 7.10, 5. intrauterine fetal death, 6)intrapartal death. inclusion: all pregnancies in stockholm with a fetus, born between 2014 and 2017 and without chromosomal abnormalities or other structural abnormalities, will be included in the project.

Eligibility criteria:
inclusion criteria: * all pregnancies in stockholm with a fetus, born between 2014 and 2017 and without chromosomal abnormalities or other serious structural abnormalities, will be included in the project. exclusion criteria: * pregnancies with known chromosomal abnormalities or other serious structural abnormalities

Keywords: iugr sga
study to investigate bronchial arterrial infusing (bai) plus three-dimensional conformal radiotherapy (3dcrt) in local advanced non-small cell lung cancer (nsclc)

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study is to investigate the efficacy of bai plus 3dcrt in local advanced nsclc.


Eligibility criteria:
inclusion criteria: * stage iiia\&iiib nsclc * male or female, age ≥18years, ≤70years * life expectation of at least 12weeks. * ps performance 0-2 * measurable disease according to the response evaluation criteria in solid tumours ( recist) exclusion criteria: * patient with prior chemotherapy or radiology for iiia or iiib nsclc

Keywords: bai 3dcrt
evolution of protective immunization against covid-19 among hospital workers in health care facilities

Conditions: Covid19

Summary: to measure the immunization rate (seroneutralization) in a population of exposed hospital workers (nursing staff assigned to dedicated covid-19 care units, laboratory staff handling covid-19 samples).

current studies on seroconversion and the time course of immunity following exposure to sars-cov-2 do not document: i) seroconversion in populations in repeated and frequent contact with patients; ii) the temporal dynamics of seroconversion at medium term. these two elements are however fundamental in the comprehension and management of this epidemic or of its potential resurgence in the following months and years. objective: to measure the immunization rate (seroneutralization) in a population of exposed hospital workers (nursing staff assigned to dedicated covid-19 care units, laboratory staff handling covid-19 samples). secondary objectives: 1. determine the kinetics of the protective response over 12 months (4 times). 2. compare immunization profiles according to: gender, age, lockdown, blood type, occupational class, exposure, asymptomatic/symptomatic. 3. compare immunization kinetics between exposed and low-exposure hospital workers. 4. to determine the characteristics of the elisa test in comparison with the reference test (seroneutralization). perspectives * to provide a reliable, affordable and faster serological test. * understanding of the natural evolution of seroprotection in a population over time. * sensitization to plasma donation for seropositive patients.

Eligibility criteria:
inclusion criteria: cohort of exposed hospital workers - hospital caregiver or non-clinician agreeing to participate in the study defined as: healthcare personnel (physician, nurse, orderly, physical therapist, midwives) who have worked for a minimum of 2 weeks since march 1, 2020 in a care unit dedicated to the management of patients confirmed or suspected of covid-19 infection, in the participating centers: intensive care units, emergency rooms, covid-19 units; * staff (physician, technician) who have worked for a minimum of 2 weeks since march 1, 2020 in the ap-hm laboratories handling samples from patients confirmed or suspected of having covid-19 infection * person affiliated to a social security system cohort of 'unexposed' hospital workers * hospital care worker (physician, nurse, orderly) willing to participate in the study who has not worked since march 1, 2020 in an intensive care unit or emergency department or other department dedicated to the management of patients confirmed or suspected of having covid-19 infection. * person affiliated with a social security system exclusion criteria: * hospital worker declining to participate if the hospital worker changes assignment after the first collection, he/she remains in the exposed cohort. * protected adult * person under legal guardianship or curatorship

Keywords: serology healthcare workers
use of synvisc® in knee osteoarthritis - survey on practice

Conditions: Osteoarthritis

Summary: study of prescription methods in everyday medical practice, tolerance profile and effect of synvisc® until six months of follow-up.


Eligibility criteria:
inclusion criteria: * not applicable exclusion criteria: * none
an eight-week study of ssr411298 as treatment for major depressive disorder in elderly patients

Conditions: Major Depressive Disorder

Summary: the primary objective of this study is to evaluate the efficacy of 3 fixed doses of ssr411298 (10, 50 or 200 mg daily) compared to placebo, in elderly patients with major depressive disorder (mdd), based on the 17-item hamilton depression rating scale. secondary objectives are: * to evaluate the tolerability and safety of an 8-week treatment with ssr411298 versus placebo in elderly patients with mdd. * to evaluate the effect of ssr411298 on disability, anxiety, cognitive function, sleep, pain and somatic symptoms related to depression, and bone markers. * to assess ssr411298 plasma concentrations. * to assess plasma endocannabinoid concentrations.

the study period for a participants is approximately 10 weeks including a screening up to 1 week, 8-week treatment and 1-week follow-up.

Eligibility criteria:
inclusion criteria: * elderly patient with recurrent major depressive disorder exclusion criteria: * duration of current depressive episode greater than 2 years; * mild depression as measured by standard clinical research scales; * cognitive disturbance; * significant suicide risk; * other psychiatric conditions that would obscure the results of the study; * history of failure to respond to antidepressant treatment. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: depression major depressive episode antidepressant
safety and efficacy on phase iii study on 300 ir slit to patients suffering from grass pollen rhinoconjunctivitis

Conditions: Primary Disease

Summary: the purpose of this study is to evaluate the efficacy and safety of sublingual tablets of grass pollen allergen extract when initiated 2 months before the grass pollen season compared with placebo for reduction of rhinoconjunctivitis symptoms and rescue medication usage.

to assess the efficacy of sublingual tablets of grass pollen allergen extract when initiated 2 months before the grass pollen season on: - the average adjusted symptom score (aass). to document the safety of the treatment.

Eligibility criteria:
inclusion criteria: 1. male or female outpatients aged 12 to 65 years (inclusive). 2. patients with grass pollen-related allergic rhinoconjunctivitis for at least the last two grass pollen seasons. 3. positive spt 4. rrtss during the previous pollen season of greater than or equal to 12 out of a possible 18. exclusion criteria: 1. positive spt to any other seasonal allergens present during the grass pollen season 2. patients with clinically significant confounding symptoms of allergy to other allergens 3. significant symptomatic perennial allergy due to an allergen to which the patient is regularly exposed. 4. patients with moderate or severe persistent asthma (global initiative for asthma \[gina\] 3 or 4).

Keywords: allergic rhinoconjunctivitis